SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F

Market Overview

Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.

Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.

Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.

Surge in Technological Advancements

The global SGLT2 inhibitors market is experiencing robust growth, largely propelled by significant technological advancements in pharmaceutical research and development. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a new class of insulin-independent anti-hyperglycemic agents that function independently of β-cells. Multiple large-scale clinical trials have demonstrated the cardiovascular protective benefits of SGLT2is in both diabetic and non-diabetic patients. Innovations in drug formulation, targeted delivery systems, and precision medicine have enhanced the efficacy and safety profiles of SGLT2 inhibitors, making them a preferred therapeutic option for managing type 2 diabetes and associated cardiovascular conditions.

Cutting-edge technologies such as advanced biomarker identification, high-throughput screening, and AI-driven drug discovery are accelerating the development of novel SGLT2 inhibitors with improved therapeutic outcomes. Additionally, improvements in manufacturing processes and quality control are ensuring greater consistency and scalability, enabling pharmaceutical companies to meet the rising global demand more efficiently. As a result, the integration of these technological breakthroughs is expected to sustain market momentum and open new growth avenues within the competitive landscape of the SGLT2 inhibitors market.

Download Free Sample Report

Key Market Challenges

High Cost of Therapy

One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.

The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.

Key Market Trends

Rising Prevalence of Diabetes

The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.

Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.

Segmental Insights

Drug Insights

Based on Drug, Jardiance have emerged as the fastest growing segment in the Global SGLT2 Inhibitors Market in 2024. This is due to its strong clinical efficacy and expanding therapeutic indications. Backed by robust clinical trial data, Jardiance has demonstrated significant benefits not only in glycemic control but also in reducing cardiovascular and renal risks, which has widened its appeal among healthcare providers and patients alike. The drug’s approval for multiple indications, including type 2 diabetes, heart failure, and chronic kidney disease, has further bolstered its market penetration.

Indication Insights

Based on Indication, Cardiovascular have emerged as the fastest growing segment in the Global SGLT2 Inhibitors Market during the forecast period. This is due to the expanding recognition of these drugs’ significant benefits beyond glucose control. Extensive clinical trials have demonstrated that SGLT2 inhibitors not only improve glycemic management but also provide substantial cardiovascular protection, including reductions in heart failure hospitalizations and major adverse cardiovascular events. This dual benefit has led to wider adoption among patients with cardiovascular conditions, even those without diabetes.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global SGLT2 Inhibitors Market in 2024. This is due to a convergence of factors including a high prevalence of type 2 diabetes and related cardiovascular and renal complications, well-established healthcare infrastructure, and strong regulatory support. The region benefits from advanced healthcare systems that facilitate early diagnosis and effective management of chronic diseases, creating significant demand for innovative therapies like SGLT2 inhibitors.

Recent Development

• In 2024, the FDA approved several SGLT2 inhibitors, including canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin. For individuals with type 2 diabetes mellitus (T2DM), it is recommended that these medications be used alongside improved diet and physical activity to effectively manage blood glucose levels. These drugs can be prescribed as monotherapy or in combination with other diabetes treatments, such as metformin.
• In June 2024, AstraZeneca’s Farxiga (dapagliflozin) received FDA approval to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes (T2D). This approval was supported by positive outcomes from the pediatric T2NOW Phase III trial. Farxiga was previously approved in the US for adults with T2D as an adjunct to diet and exercise to enhance glycemic management.
• In January 2024, Huisheng Biopharmaceutical Co. Ltd., based in Jilin, China, received approval from the China NMPA for Huiyoujing (proline janagliflozin tablets), its independently developed sodium-glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes. This regulatory clearance makes janagliflozin the second domestically produced SGLT2 inhibitor in China, following Jiangsu Hengrui Medicine Co. Ltd.’s henagliflozin (SHR-3824), which was launched in May 2022.
• In March 2025, USV, an Indian multinational healthcare company, launched Xenia (empagliflozin and its combinations), a leading SGLT2 inhibitor for glycemic control, heart failure, and chronic kidney care in patients with type 2 diabetes. The product portfolio includes Xenia (empagliflozin 10 mg & 25 mg), Xenia M (empagliflozin 12.5 mg + metformin 500 mg IR / 1000 mg ER), and Xenia ST (empagliflozin 25 mg + sitagliptin 100 mg). These formulations provide flexible dosing, reduce pill burden, and improve access to advanced therapies, facilitating early intervention to lower diabetes-related complications and mortality.

Key Market Players

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• SGLT2 Inhibitors Market, By Drug:

o   Jardiance

o   Farmiga

o   Inpefa

o   Invokana

o   Others

• SGLT2 Inhibitors Market, By Indication:

o   Type 2 Diabetes

o   Cardiovascular

o   Others

• SGLT2 Inhibitors Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.

Available Customizations:

Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global SGLT2 Inhibitors Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]